Sarepta Therapeutics (SRPT) Tops Q4 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments
March 1, 2022 4:05 PM ESTTotal revenues, which consist primarily of net product revenues and collaboration revenues, for the fourth quarter and full-year 2021 totaled $201.5 million and $701.9 million, respectivelyNet product revenues for the fourth quarter and full-year 2021 totaled $178.7 million and $612.4 million, respectively Fourth quarter 2021 net product revenues increased approximately 46% over the fourth quarter of 2020; full-year 2021 net product revenues increased approximately 34% over the prior year
CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare... More
